Skip to content
Quant500 - Quantitative Analysis
Search ticker or company...
ES | EN

Company Profile: Viatris Inc. (VTRS)

VTRS insider trades (13 months) →

$18.92 +1.34% vs. previous close · Market cap $21.73B

Today's multi-factor rank: 76 of 461 · see the ranking

Quant500 Scores
Momentum
8.1/10
Value
6.2/10
Growth
4.5/10
Quality
3.1/10
Multifactor
5.5/10

Market and Valuation

Price & Market

Prev Close Price:$18.67
Open:$18.70
Day's Low:$18.64
Day's High:$18.94
Bid / Ask:-
Market Cap:21.73B
Enterprise Value:33.56B

52-Week Range

52-Week Low:$9.92
52-Week High:$19.51
Current position in 52-week range
52w Low-52w High
50-Day Avg:$17.50
200-Day Avg:$15.92

Volume

Volume Today:7,549,918
Avg Volume (3m):9,092,395
Avg Volume (10d):8,362,140
52-Week Change:+77.98%
vs S&P 500, 52 weeks:-
Beta:0.87

Valuation Multiples

P/E (trailing):n/a (loss)

Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 6, 2026. With negative EPS a P/E means nothing, so it is not shown.

P/E (forward):7.00
PEG Ratio:3.40
Price / Book:1.53
Price / Sales (TTM):1.47
EV / Revenue:2.28
EV / EBITDA:7.82

Dividends

Current yield:2.57%
Annual Dividend Rate:$0.48
Dividend Trailing:$0.48
Yield Trailing:2.57%
5-Year Avg Yield:3.93%
Payout Ratio:960.00%
Last Ex-Dividend Date:-

Valuation Context

P/E vs sector (indicative)

Most Recent Quarter:-
Fiscal Year (Next):-

Loading historical OHLCV database...

Financial Statements TTM (Trailing 12 Months)

Income Statement

Total Revenue (TTM):14.74B
Gross Profit:5.94B
EBITDA:4.29B
Net Income (TTM):−410.70M
Rev Growth (YoY):+4.90%
Earnings Growth (YoY):-
Quarterly earnings growth (YoY):-

Margins

Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-

Per Share

EPS Trailing (TTM):$-0.36

Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 6, 2026. With negative EPS a P/E means nothing, so it is not shown.

EPS Forward (Est.):$2.70
Revenue Per Share:$12.72
Cash Per Share:-
Book Value:$12.34
Last Dividend:-
Ex-Dividend Date:-
Last Split:-

Balance Sheet & Liquidity

Total cash:1.51B
Total Debt:13.62B
Net Debt (Debt - Cash):12.11B
Debt / Equity:95.54%
Current Ratio:1.59
Quick Ratio:0.82

Cash Flows

Operating Cash Flow:2.33B
Free Cash Flow (FCF):2.68B
FCF Yield (FCF / Market Cap):-
Enterprise Value:33.56B
EV / Revenue:2.28
EV / EBITDA:7.82

Profitability

ROE (Return on Equity):-2.75%
ROA (Return on Assets):2.67%
P/E (trailing):n/a (loss)
P/E (forward):7.00
Price / Book:1.53
PEG Ratio:3.40
52-Week Change:+77.98%
S&P 500 change, 52 weeks:+11.37%

Historical Evolution (Last 4 Years)

Income Statement

Balance Sheet

Cash Flow

EPS and Earnings Per Share

Key EPS Metrics

EPS Trailing (TTM):$-0.36

Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 6, 2026. With negative EPS a P/E means nothing, so it is not shown.

EPS Forward (Est.):$2.70
P/E (forward):7.00
PEG Ratio:3.40

Growth and Margins

Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-

Per Share

Revenue Per Share:$12.72
Cash Per Share:-
Book Value:$12.34

Cash Flows (TTM)

Free Cash Flow:2.68B
Operating Cash Flow:2.33B
EBITDA:4.29B
Total Revenue (TTM):14.74B
Net Income (TTM):−410.70M
Fiscal Year (Last):-

EPS Surprise History - Last 4 Quarters

Actual vs. Analyst Estimates · Green = beat expectations · Red = missed

Quarter Period Actual EPS Estimated EPS Difference Surprise % Currency

Ownership Structure

Ownership Distribution

% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float

Shares & Short Interest

Shares Outstanding:1,148,590,864
Float (free shares):1,141,791,206
Short interest (shares):37,926,100
Short % of float:-
Short Ratio (days to cover):4.13
Short interest, prior month:-
Short Interest Date:-

Governance Score (1=Best, 10=Worst)

Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-

Top Institutional Holders

Position Change: ▲ Increased · ▼ Reduced · = Unchanged

Organization Report Date % Shares No. Shares Value (USD) Change %

Top Mutual Funds

Position Change: ▲ Increased ▼ Decreased = Unchanged

Fund Report Date % Shares No. Shares Value (USD) Change %

Recent Insider Trades

Executive / Insider Title Date Action Shares

Options Chain

CALLS

StrikeLastBidAskVol.O.I.IV

PUTS

StrikeLastBidAskVol.O.I.IV

Viatris Inc. (VTRS) SEC filings: 10-K, 10-Q and 8-K

Direct links to financial reports filed with the SEC.

Type Date Official link
8-K2026-10-08View filing ↗
10-Q2026-08-06View filing ↗
8-K2026-07-01View filing ↗
8-K2026-06-18View filing ↗
8-K2026-06-15View filing ↗
8-K2026-05-15View filing ↗
10-Q2026-05-07View filing ↗
8-K2026-05-04View filing ↗
ARS2026-04-02View filing ↗
10-K2026-02-26View filing ↗

Company and Executive Profile

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

General Information

Headquarters:United States
City:Canonsburg
Employees:30,000
Sector:Healthcare
Industry:Drug Manufacturers - Specialty & Generic
Website:-

Key Executives

NameTitleAgeTotal pay
Mr. Scott Andrew Smith Ph.D.CEO & Director635.12M
Mr. Andrew EnriettiChief Administrative & Transformation Officer401.94M
Dr. Corinne M. Le Goff M.B.A., Pharm.D.Chief Commercial Officer602.33M
Mr. Paul B. CampbellInterim CFO, Chief Accounting Officer & Corporate Controller583.70M
Mr. Ramkumar V. RayapureddyChief Information Officer--
Mr. William Szablewski C.F.A.Head of Investor Relations & Capital Markets--
Mr. Matthew Joseph MalettaChief Legal Officer53-
Ms. Lara RamsburgChief People & Corporate Affairs Officer--

You have seen the engine room

A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.

No card. No spam.

Viatris Inc. (VTRS): Quantitative Analysis

Viatris Inc. (VTRS) — Healthcare — Drug Manufacturers - Specialty & Generic. VTRS is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.

So far in 2026, VTRS has returned +54.9% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.

VTRS ranks 76 of 461 on today's multifactor score, and 7 of the 55 Healthcare companies that score. Its strongest factor is momentum (Z 1.89, ranked 21 of 494); its weakest is quality (Z -1.12, ranked 457 of 468). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.

Factor scores

The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.

FactorZ-ScoreRank
Multifactor0.29676 of 461
Momentum1.89021 of 494 ↑1
Value0.70966 of 489 ↓4
Quality-1.115457 of 468
Growth-0.302334 of 489

Market data

MetricValue
Price$18.92
Market Cap21.73B
Forward P/E (estimate)7.00
Revenue (last 12 months)14.74B
Price / book1.53
Book value per share$12.34
52-week range$9.92 – $19.51
Dividend yield2.57%
Beta0.87
Average volume9,092,395
Shares outstanding1.15B
Short interest (% of float)3.31% (as of Oct 15, 2026)

When does VTRS report earnings? 10 of its last 11, before the open →

What are VTRS insiders doing? 51 transactions filed with the SEC, of them 2 buys and 3 sells, the last one on Aug 15, 2026 →

VTRS latest SEC filings

Filing dates on EDGAR, the SEC's public registry. All VTRS filings on EDGAR.

Guides: How to read a Quant500 company page · What the S&P 500 is · P/E ratio explained · 10-K, 10-Q and 8-K · all guides

Frequently asked questions about Viatris (VTRS)

When does Viatris report earnings?

According to Nasdaq's public calendar (checked on Nov 4, 2026), Viatris will report its next earnings on Nov 5, 2026, before the US market opens. The date is announced by the company itself and can change. Of its last 12 earnings announcements: 1 after the close and 10 before the open (and 1 with no time on the filing) (SEC filings through Aug 6, 2026). VTRS earnings dates and times, quarter by quarter →

Where does Viatris rank on Quant500?

In the Nov 3, 2026 multi-factor ranking, Viatris ranks 76 of 461, and 7 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking → How it is calculated →

Have Viatris insiders bought or sold shares?

The latest open-market purchase of Viatris shares filed with the SEC (Form 4) was on Nov 3, 2025, by a director, for $2k. The latest sale was on Jun 25, 2026, by an officer, for $810k. In total, from August 2025 through Nov 3, 2026: 2 purchases and 3 sales by directors, officers and large shareholders. All VTRS insider trades →

Does Viatris pay a dividend?

Yes. Its dividend yield is 2.57% at the Nov 3, 2026 close (annual dividend of $0.48 per share). The latest recorded ex-dividend date is Aug 21, 2026.

What sector is Viatris in, and which index?

Viatris is classified in the Healthcare sector (industry: Drug Manufacturers - Specialty & Generic), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →

What is behind these numbers

The concepts on this page, explained from scratch in the Academy. Free, no account.

The whole Academy, course by course →

Data as of Nov 3, 2026. Source: point-in-time SEC fundamentals and closing prices. Method and formulas are on the home page.

The model portfolio, weekly in your inbox

Every Saturday, its week in one minute: how it went, the best and the worst, and which insiders bought with their own money. Plus, the day the model is rebuilt, which stocks come in and which go out. A simulation, not advice. At most one email a week, no ads, no account; one-click unsubscribe. Made by one person: Pol Gracia.

A model portfolio with simulated results, not a personalized recommendation. Your email is used for this only: privacy.

S&P 500 market gravity